-
公开(公告)号：US09376684B2
公开(公告)日：2016-06-28
申请号：US13050120
申请日：2011-03-17
IPC分类号： A61K48/00 , A61K39/00 , C07H21/04 , C07K14/00 , C12N15/63 , C12N15/62 , C07K14/73 , C07K14/74 , C07K14/705 , C07K14/81 , C07K14/815 , C12N9/64 , C12N15/85 , A61K38/00
CPC分类号： C12N15/62 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/072 , A01K2227/10 , A01K2227/103 , A01K2227/108 , A01K2267/01 , A01K2267/02 , A01K2267/025 , A61K38/00 , A61K48/00 , C07H21/04 , C07K14/70514 , C07K14/70539 , C07K14/70564 , C07K14/70571 , C07K14/8114 , C07K14/815 , C07K2319/00 , C07K2319/03 , C07K2319/033 , C07K2319/32 , C07K2319/74 , C12N9/6418 , C12N15/63 , C12N15/8509 , C12N2799/027
摘要： The invention relates to the inhibition of blood coagulation, especially during organ rejection, and in particular the inhibition of delayed vascular rejection. The invention provides anticoagulant proteins which are anchored to cell membranes. The anticoagulant function is preferably provided by heparin, antithrombin, hirudin, TFPI, tick anticoagulant peptide, or a snake venom factor. These anticoagulant proteins are preferably prevented from being constitutively expressed at the cell surface. In particular, expression at the cell surface is regulated according to cell activation, for instance by targeting the protein to a suitable secretory granule. Expression of these proteins renders cells, tissues and organs less vulnerable to rejection after transplantation (e.g. after xenotransplantation).
摘要翻译： 本发明涉及抑制血液凝固，特别是在器官排斥期间，特别是对延迟血管排斥的抑制。 本发明提供了锚定于细胞膜的抗凝血蛋白。 抗凝血功能优选由肝素，抗凝血酶，水蛭素，TFPI，蜱抗凝肽或蛇毒因子提供。 优选地防止这些抗凝血蛋白在细胞表面组成型表达。 特别地，细胞表面的表达根据细胞活化来调节，例如通过将蛋白质靶向合适的分泌颗粒。 这些蛋白质的表达使细胞，组织和器官在移植后不易受到排斥（例如在异种移植后）。
-
2.发明授权公开(公告)号：US08759066B2
公开(公告)日：2014-06-24
申请号：US12935235
申请日：2009-04-07
CPC分类号： C12N9/6418 , C07K2319/50
摘要： Disclosed are compositions for activating thrombin precursors to thrombin. The compositions provided include polypeptide compositions wherein the pre-pro-sequence comprises a thrombin cleavage site. The compositions provided also include polynucleotides encoding said polypeptides and recombinant systems for expressing said polypeptides. This disclosure also relates to methods for producing said compositions, recovering said compositions, activating said compositions purifying said compositions and producing active thrombin molecules using the active form of said compositions.
摘要翻译： 公开了用于激活凝血酶凝血酶前体的组合物。 提供的组合物包括多肽组合物，其中前序列包含凝血酶切割位点。 提供的组合物还包括编码所述多肽的多核苷酸和用于表达所述多肽的重组系统。 本公开还涉及生产所述组合物的方法，回收所述组合物，使用所述组合物的活性形式活化所述组合物来纯化所述组合物并产生活性凝血酶分子。
-
3.发明授权Inhibiting integrin receptor binding with non-native monomeric disintegrin or monomeric disintegrin domains 有权抑制整合素受体与非天然单体解体蛋白或单克隆蛋白结合域的结合公开(公告)号：US08338365B2
公开(公告)日：2012-12-25
申请号：US13367267
申请日：2012-02-06
CPC分类号： C12P21/00 , A61K38/1703 , C07K14/245 , C07K2319/00 , C07K2319/21 , C07K2319/50 , C07K2319/90 , C12N9/6418 , C12N9/90 , C12P21/02
摘要： This invention relates to methods of inhibiting binding between a cell expressing integrin receptors specific for one or more integrins selected from the group consisting of αIIbβ3, αvβ3, αvβ5, or α5β1, said method comprising contacting the cell with a monomeric disintegrin or monomeric disintegrin domain which comprises a C-terminal sequence non-native to the disintegrin or disintegrin domain, said C-terminal sequence encoding a functional integrin-binding loop.
摘要翻译： 本发明涉及抑制一种表达整合素受体特异性的细胞与选自αIIb和bgr; 3，αv＆bgr; 3，αv＆bgr; 5或α5和bgr之间的结合的方法，所述方法包括使细胞与 单体的整合素或单体的整合蛋白结构域，其包含非整数酶解整合素结构域的C-末端序列，所述C-末端序列编码功能性整联蛋白结合环。
-
4.发明申请CLONING AND RECOMBINANT PRODUCTIONS OF VESPULA VENOM PROTEASE AND METHODS OF USE THEREOF 有权VESPULA VENOM PROTEASE的克隆和重组生产及其使用方法公开(公告)号：US20120009187A1
公开(公告)日：2012-01-12
申请号：US13254644
申请日：2010-03-03
申请人： Henning Seismann , Ingke Braren , Thomas Grunwald
发明人： Henning Seismann , Ingke Braren , Thomas Grunwald
IPC分类号： A61K39/395 , A61K38/48 , G01N33/573 , C12N9/96 , C12N9/50 , C07H21/04 , A61P37/08 , C12N1/21 , C12N1/19 , C40B30/04 , A61K31/7088 , A61K38/54 , C12N5/10
CPC分类号： A61K39/35 , C12N9/6418
摘要： The invention relates to nucleic acids encoding a novel Vespula venom protease or fragments thereof, in particular the protease Ves v 4, recombinant vectors comprising such nucleic acids, and host cells containing the recombinant vectors. The invention is further directed to the expression of such nucleic acids to produce a recombinant Vespula venom protease, or recombinant fragments thereof, or synthetic peptides thereof. Such a protease or fragments thereof or synthetic peptides thereof are useful for diagnosis of insect venom allergy and for therapeutic treatment of insect venom allergy.
摘要翻译： 本发明涉及编码新型蛇毒毒蛋白酶或其片段的核酸，特别是蛋白酶Ves v4，包含该核酸的重组载体和含有重组载体的宿主细胞。 本发明进一步涉及这种核酸的表达以产生重组Vespula毒液蛋白酶或其重组片段或其合成肽。 这种蛋白酶或其片段或其合成肽可用于昆虫毒液过敏的诊断和昆虫毒液过敏的治疗处理。
-
5.发明申请公开(公告)号：US20110151536A1
公开(公告)日：2011-06-23
申请号：US12935235
申请日：2009-04-07
CPC分类号： C12N9/6418 , C07K2319/50
摘要： Disclosed are compositions for activating thrombin precursors to thrombin. The compositions provided include polypeptide compositions wherein the pre-pro-sequence comprises a thrombin cleavage site. The compositions provided also include polynucleotides encoding said polypeptides and recombinant systems for expressing said polypeptides. This disclosure also relates to methods for producing said compositions, recovering said compositions, activating said compositions purifying said compositions and producing active thrombin molecules using the active form of said compositions.
摘要翻译： 公开了用于激活凝血酶凝血酶前体的组合物。 提供的组合物包括多肽组合物，其中前序列包含凝血酶切割位点。 提供的组合物还包括编码所述多肽的多核苷酸和用于表达所述多肽的重组系统。 本公开还涉及生产所述组合物的方法，回收所述组合物，使用所述组合物的活性形式活化所述组合物来纯化所述组合物并产生活性凝血酶分子。
-
公开(公告)号：US07754850B2
公开(公告)日：2010-07-13
申请号：US11351311
申请日：2006-02-09
CPC分类号： C12P21/00 , A61K38/1703 , C07K14/245 , C07K2319/00 , C07K2319/21 , C07K2319/50 , C07K2319/90 , C12N9/6418 , C12N9/90 , C12P21/02
摘要： This invention relates to methods of expressing eukaryotic proteins in prokaryotic hosts, particularly eukaryotic proteins that require formation of disulfide bridges for biological activity. Various approaches are used including fusion to thioredoxin, cytoplasmic expression of disulfide isomerases, deficiencies in thioredoxin and/or glutathione reductases, deficiencies in proteases, and the like. The method is applicable to express monomeric and dimeric forms of the eukaryotic protein with biological activity such as monomeric and dimeric forms of a disintegrin or a disintegrin domain. Included are the vectors, host cells expressing the proteins, the expressed proteins and methods of using the proteins.
摘要翻译： 本发明涉及在原核宿主中表达真核蛋白的方法，特别是需要形成用于生物活性的二硫键的真核蛋白。 使用各种方法，包括硫氧还蛋白的融合，二硫键异构酶的细胞质表达，硫氧还蛋白和/或谷胱甘肽还原酶的缺陷，蛋白酶的缺陷等。 该方法适用于表达具有生物学活性的单核和二聚形式的真核生物蛋白，例如单克隆或二聚体形式的解整合素或去整合素结构域。 包括载体，表达蛋白质的宿主细胞，表达的蛋白质和使用蛋白质的方法。
-
公开(公告)号：US20050118160A1
公开(公告)日：2005-06-02
申请号：US10101523
申请日：2002-03-18
IPC分类号： A01K67/027 , A61K38/00 , A61K48/00 , A61P7/02 , A61P37/06 , C07K14/705 , C07K14/73 , C07K14/74 , C07K14/81 , C07K14/815 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N9/64 , C12N15/09 , C12N15/62 , C12N15/85 , H04W4/00 , C07H21/04 , A61K38/48
CPC分类号： C12N15/62 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/072 , A01K2227/10 , A01K2227/103 , A01K2227/108 , A01K2267/01 , A01K2267/02 , A01K2267/025 , A61K38/00 , A61K48/00 , C07H21/04 , C07K14/70514 , C07K14/70539 , C07K14/70564 , C07K14/70571 , C07K14/8114 , C07K14/815 , C07K2319/00 , C07K2319/03 , C07K2319/033 , C07K2319/32 , C07K2319/74 , C12N9/6418 , C12N15/63 , C12N15/8509 , C12N2799/027
摘要： The invention relates to the inhibition of blood coagulation, especially during organ rejection, and in particular the inhibition of delayed vascular rejection. The invention provides anticoagulant proteins which are anchored to cell membranes. The anticoagulant function preferably provided by heparin, antithrombin, hirudin, TFPI, tick anticoagulant peptide, or a snake venom factor. These anticoagulant proteins are preferably prevented from being constitutively expressed at the cell surface. In particular, expression at the cell surface is regulated according to cell activation, for instance by targeting the protein to a suitable secretory granule. Expression of these proteins renders cells, tissues and organs less vulnerable to rejection after transplantation (e.g. after xenotransplantation).
摘要翻译： 本发明涉及抑制血液凝固，特别是在器官排斥期间，特别是对延迟血管排斥的抑制。 本发明提供了锚定于细胞膜的抗凝血蛋白。 抗凝血功能优选由肝素，抗凝血酶，水蛭素，TFPI，蜱抗凝肽或蛇毒因子提供。 优选地防止这些抗凝血蛋白在细胞表面组成型表达。 特别地，细胞表面的表达根据细胞活化来调控，例如通过将蛋白质靶向合适的分泌颗粒。 这些蛋白质的表达使细胞，组织和器官在移植后不易受到排斥（例如在异种移植后）。
-
公开(公告)号：US20040091887A1
公开(公告)日：2004-05-13
申请号：US10383588
申请日：2003-03-10
发明人： Yaw-Wen Guo , Pei-Hsun Ho
IPC分类号： C12Q001/68 , A01K067/00 , C12N009/64 , C07H021/04
CPC分类号： C12N9/6416 , A01K2217/05 , C07H21/04 , C07K2319/00 , C12N9/6418
摘要： Novel Mucroslysin protein and nucleic acid molecules are disclosed. The invention provides purified Mucroslysin protein, fusion protein, antigenic peptides, and anti-Mucroslysin antibodies. The invention also provides isolated Mucroslysin nucleic acid molecule, recombinant vectors containing the Mucroslysin nucleic acid molecule, host cells containng the recombinant vector, and non-human transgenic animals in which the Mucroslysin nucleic acid molecule has been introduced.
摘要翻译： 公开了新型的米考糖蛋白和核酸分子。 本发明提供了纯化的粘液蛋白酶蛋白，融合蛋白，抗原肽和抗粘蛋白溶素抗体。 本发明还提供了分离的莫克斯新淡葡聚糖核酸分子，含有核糖核酸分解酶的重组载体，含有重组载体的宿主细胞和其中引入了核糖核酸分解素的非人转基因动物。
-
公开(公告)号：US06489451B1
公开(公告)日：2002-12-03
申请号：US09058740
申请日：1998-04-10
申请人： Benjamin Xy Li , Xin Cheng
发明人： Benjamin Xy Li , Xin Cheng
IPC分类号： C07K1400
CPC分类号： C12N9/6418 , A61K38/00 , Y10S530/856
摘要： This invention features an antithrombosis enzyme extracted and purified from the snake venom of Southern-Anhui Agkistrodon acutus and pharmaceutical uses thereof.
摘要翻译： 本发明特征在于从南安徽Ag蛇蛇毒提取和纯化的抗血栓形成酶及其药物用途。
-
公开(公告)号：US06423316B1
公开(公告)日：2002-07-23
申请号：US09402515
申请日：2000-02-02
IPC分类号： A61K3900
CPC分类号： C12N15/62 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/072 , A01K2227/10 , A01K2227/103 , A01K2227/108 , A01K2267/01 , A01K2267/02 , A01K2267/025 , A61K38/00 , A61K48/00 , C07H21/04 , C07K14/70514 , C07K14/70539 , C07K14/70564 , C07K14/70571 , C07K14/8114 , C07K14/815 , C07K2319/00 , C07K2319/03 , C07K2319/033 , C07K2319/32 , C07K2319/74 , C12N9/6418 , C12N15/63 , C12N15/8509 , C12N2799/027
摘要： The invention relates to the inhibition of blood coagulation, especially during organ rejection, and in particular the inhibition of delayed vascular rejection. The invention provides anticoagulant proteins which are anchored to cell membranes. The anticoagulant function preferably provided by heparin, antithrombin, hirudin, TFPI, tick anticoagulant peptide, or a snake venom factor. These anticoagulant proteins are preferably prevented from being constitutively expressed at the cell surface. In particular, expression at the cell surface is regulated according to cell activation, for instance by targeting the protein to a suitable secretory granule. Expression of these proteins renders cells, tissues and organs less vulnerable to rejection after transplantation (e.g. after xenotransplantation).
摘要翻译： 本发明涉及抑制血液凝固，特别是在器官排斥期间，特别是对延迟血管排斥的抑制。 本发明提供了锚定于细胞膜的抗凝血蛋白。 抗凝血功能优选由肝素，抗凝血酶，水蛭素，TFPI，蜱抗凝肽或蛇毒因子提供。 优选地防止这些抗凝血蛋白在细胞表面组成型表达。 特别地，细胞表面的表达根据细胞活化来调节，例如通过将蛋白质靶向合适的分泌颗粒。 这些蛋白质的表达使细胞，组织和器官在移植后不易受到排斥（例如在异种移植后）。
-
-
-
-
-
-
-
-
-
搜索结果
86 条记录 (耗时 0.049 秒)